AlphAIAlphAI — Financial news for AI agents
investing.comOCT 212 min read$ISRG

Stifel reiterates Intuitive Surgical stock rating after Q3 beat

Stifel maintained its Buy rating and $550 target on Intuitive Surgical (ISRG) after Q3 2026 results beat estimates. Revenue grew 20.66% YoY, with procedure growth of 10% in the U.S. and 20% internationally. Analysts have mixed views on the stock, with targets ranging from $400 to $500. Management expects strategic initiatives to boost growth.

Original reporting
investing.com
Published Oct 21, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 1:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ISRG
Bullish
high confidence
Mentioned
$ISRG
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ISRGBullishMed
01

Why it matters

Earnings beat reinforces bullish outlook, but settlement and slower growth metrics introduce risk.

02

Market read

The earnings surprise and rating reiteration provide a fresh catalyst for ISRG, likely influencing short‑term price action.

03

What to watch

Potential impact of pricing actions in China and extended‑use program on future margins.

Relevance 8/10Novelty 8/10Timing: after‑hours reaction

Background

Intuitive Surgical is a leading maker of robotic surgical systems; its Q3 results are closely watched for growth trends.

Company-level read

Ticker impact

$ISRGBullishHigh confidence
Context

Intuitive Surgical reported Q3 revenue of $3.05 bn and EPS of $3.00, beating forecasts and prompting Stifel to reiterate its Buy rating with a $550 price target.

Expected impact

likely upward pressure as investors price in the beat and higher target

Evidence & confidence

Revenue and EPS exceeded expectations; Stifel maintains Buy with a higher target, indicating confidence in continued growth.

Market effects

Sector

Strong earnings may lift other healthcare equipment stocks.

Regional

U.S. markets may see modest gains in medical device sector.

Global

Limited to investors focused on U.S. healthcare equities.

Counterpoint

What could challenge this read

The $450 m litigation settlement and slower procedure growth could temper upside.

Key entities

  • company
    Intuitive Surgical

    Robotic surgery device manufacturer (NASDAQ: ISRG).

  • analyst
    Stifel

    Equity research firm maintaining Buy rating.

Read at source← All news

Related articles

OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Drops as $450 Million Charge Overshadows Beat

Intuitive Surgical (ISRG) reported Q3 revenue of $3.05B, up 22%, and adjusted earnings of $3.00 per share, beating expectations. However, shares fell due to a $450M antitrust settlement and a cautious growth outlook. GAAP earnings dropped to $1.49 per share, affected by the settlement. The company placed 546 da Vinci systems, with 315 being the newer da Vinci 5 platform.

finance.yahoo.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive’s shares fall 8% after tempering 2026 procedural growth outlook

Intuitive Surgical reported Q3 revenue of $3.01B, up 22% YoY, but shares fell 8% after lowering its 2026 robotic surgery procedure growth outlook to 14-15% from 13.5-15.5%. The company cited US and Chinese market headwinds. Q3 procedures grew 15% YoY, with 546 da Vinci robots placed. CEO Dave Rosa highlighted strong performance across platforms, including FDA clearance for da Vinci 5 in March 2024.

finance.yahoo.com2 min
OCT 21
$ISRGMed

Intuitive Surgical (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical (ISRG) reported strong Q3 2026 results, with da Vinci system placements up 28% globally. Da Vinci 5 and SP systems accounted for 65% of placements, and the company announced plans for a new manufacturing facility in Malaysia. ISRG also received several regulatory clearances and expects further reimbursement actions for Ion outside the U.S. The company settled a class action lawsuit related to third-party servicing of da Vinci systems.

finance.yahoo.com2 min
OCT 21
$ISRGHighAI 8/10

Intuitive Surgical Stock Falls Despite da Vinci 5 Placements Jump

Intuitive Surgical (ISRG) reported Q3 non-GAAP EPS of $3.00, beating estimates, on revenue of $3.05B, also exceeding expectations. GAAP EPS fell due to a $450M litigation charge. Shares dropped 7.76% premarket. Revenue rose 22%, driven by procedure growth and higher lease revenue. Da Vinci system placements increased to 546 from 427 a year earlier, with 315 being the new da Vinci 5 model.

finance.yahoo.com2 min